Apolipoprotein A-II: Beyond genetic associations with lipid disorders and insulin resistance

Current Opinion in Lipidology

Volumn 14, Issue 2, 2003, Pages 165-172

  Kalopissis, Athina Despina ^a   Pastier, Danièle ^a   Chambaz, Jean ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Antioxidant effects; Cholesterol efflux; Fibrates; HDL; Human apolipoprotein A II; Murine apolipoprotein A II; Transgenic mice; Very low density lipoprotein

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HEPATITIS C VIRUS; HUMAN; HYDROPHOBICITY; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LIVER PROTECTION; MEASUREMENT; NONHUMAN; PATHOGENESIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-II; CARDIOVASCULAR DISEASES; CHOLESTEROL; GLUCOSE; HEPACIVIRUS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM;

HEPATITIS C VIRUS; MURINAE; MUS MUSCULUS;

EID: 0037399153     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200304000-00008     Document Type: Review

References (64)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
2. Von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol. Curr Opin Lipidol 2000; 11:627-637.
3. Laws A, King AC, Haskell WL, Reaven GM. Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride concentrations in men. Arterioscler Thromb 1991; 11:1636-1642.
4. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol 1996; 7:217-226.
5. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-228.
6. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 2000; 106:1205-1207.
7. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996; 7:139-142.
8. Tailleux A, Duriez P, Fruchart J-C, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002; 164:1-13. This is a broad review discussing the role of apo A-II in several aspects of HDL metabolism, with emphasis on studies with transgenic mice. A comprehensive evaluation is presented of the effects of apo A-II on enzymes and transfer proteins implicated in lipoprotein metabolism.
9. Blanco-Vaca F, Escolà-Gil JC, Martin-Campos JM, Julve J. Role of apo A-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 2001; 42:1727-1739. This broad review discusses the role of ape A-II in several aspects of HDL metabolism, with emphasis on studies with transgenic mice. It provides an interesting survey of ape A-II transcriptional regulation.
10. Middleton-Price HR, van den Berghe JA, Scott J, et al. Regional chromosomal localisation of APOA2 to 1q21-1q23. Hum Genet 1988; 79:283-285.
11. Lusis AJ, Taylor BA, Wangenstein RW, LeBoeuf RC. Genetic control of lipid transport in mice. II. Genes controlling structure of high density lipoproteins. J Biol Chem 1983; 258:5071-5078.
12. Beekman M, Heijmans BT, Martin NG, et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res 2002; 5:87-97.
13. Shelley CS, Sharpe CR, Baralle FE, Shoulders CC. Comparison of the human apolipoprotein genes. Apo AII presents a unique functional intron-exon junction. J Mol Biol 1985; 186:43-51.
14. n repeat polymorphism of the apo A-II gene on the plasma apo A-II concentrations and HDL subfractions: The ECTIM Study. Am J Med Genet 2002; 110:19-24.
15. Han Z, Heath SO, Shmulewitz D, et al. Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, federated states of Micronesia. Am J Med Genet 2002; 110:234-242. This comprehensive epidemiological and genetic study confirmed the association of the ape A-II/Mspl polymorphism with plasma triglyceride levels and reported novel associations of ape A-II/Mspl with apo A-I and blood pressure, and of CYP7α/Bsal with ape A-I and body mass index levels.
16. Chambaz J, Cardot P, Pastier D, et al. Promoter elements and factors required for hepatic transcription of the human apoA-II gene. J Biol Chem 1991; 266:11676-11685.
17. Van't Hooft FM, Ruotolo G, Boquist S, et al. Human evidence that the apolipoprotein A-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation 2001; 104:1223-1228.
18. Boisfer E, Lambert G, Atger V, et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem 1999; 274:11564-11572.
19. Pastier D, Dugue S, Boisfer E, et al. Apolipoprotein A-II/A-I ratio is a key determinant in vivo of HDL concentration and formation of pre-beta HDL containing apolipoprotein A-II. Biochemistry 2001; 40:12243-12253. This study used three human apo A-II transgenic lines with plasma ape A-II concentrations ranging from normal to four times higher. It established the dose-dependent decrease in ape A-I, displaced by the more hydrophobic human apo A-II. The feeding-fasting transition decreased ape A-II up to 40%, and normalized triglyceridemia, which was very elevated in the fed state. The formation of pre-β HDL containing human apo A-II was shown for the first time.
20. Benson MD, Liepniks JJ, Yazaki M, et al. A new human hereditary amyloidosis: The result of a stop-codon mutation in the apolipoprotein A-II gene. Genomics 2001; 72:272-277.
21. Yazaki M, Liepnieks JJ, Yamashita T, et al. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int 2001; 60:1658-1665. This interesting study reported a novel mutation leading to synthesis of a 21 residue-longer human apo A-II variant, which causes amyloidosis, as the mutation in Ref. [20]. These two mutations cause the only cases of amyloidosis due to apo A-II in humans. On the contrary, murine apo A-II often causes amyloidosis in aging mice.
22. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96:741-750.
23. Sabile A, Perlemuter G, Bone F, et al. Hepatitis C virus core protein binds to apolipoprotein A-II and its secretion is modulated by fibrates. Hepatology 1999; 30:1064-1076.
24. Berthou L, Saladin R, Yaqoog P, et al. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995; 232:179-187.
25. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, et al. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem 1996; 271:6720-6728.
26. LeBoeuf RC, Doolittle MH, Montcalm A, et al. Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. J Lipid Res 1990; 31:91-101.
27. Robins SJ. PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates. J Cardiovasc Risk 2001; 8:195-201.
28. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LpA-I, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21:1783-1789. In this interesting study the authors compared the effects of gemfibrozil and niacin in subjects with low HDL cholesterol. Lipoprotein-A-I particles were selectively increased by niacin, whereas both agents increased lipoprotein-A-I+A-II particles. Studies on HepG2 ceils showed a decreased removal of lipoprotein-A-I particles, which may account for the increased lipoprotein-A-I concentration with niacin.
29. Saucan L, Brinton EA. Lp A-I and niacin. New views of an antiatherogenic duo. Arterioscler Thromb Vasc Biol 2001; 21:1707-1709. This provides a very interesting analysis of Ref. [28•] and a discussion of clinical therapeutic treatments.
30. Stangl H, Cao G, Wyne KL, Hobbs HH. Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low density lipoproteins, and nonlipoprotein cholesterol. J Biol Chem 1998; 273:31002-31008.
31. Bortnick AE, Rothblat GH, Stoudt G, et al. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 2000; 275:28634-28640.
32. Xu S, Laccotripe M, Huang X, et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997; 38:1289-1298.
33. Tailleux A, Bouly M, Luc G, et al. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20:2453-2458.
34. Lagrost L, Dengremont C, Athias A, et al. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. J Biol Chem 1995; 270:13004-13009.
35. Castro G, Nihoul LP, Dengremont C, et al. Cholesterol efflux, lecithin:cholesterol acyltransferase activity, and pre-β particle formation by serum from human apolipoprotein A-I/ apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry 1997; 36:2243-2249.
36. Fournier N, Cogny A, Atger V, et al. Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells. Arterioscler Thromb Vasc Biol 2002; 22:638-643. This study showed that plasma from two transgenic lines of human ape A-II-expressing mice stimulated cholesterol efflux from J774 macrophages stimulated by cyclic AMP, which express ABCA1. However, the same plasma pools decreased efflux from SR-BI-expressing Fu5AH cells. At the same phospholipid concentration, ape A-II-rich HDL of transgenic mice are less efficient cholesterol accepters than control HDL.
37. Chiesa G, Parolini C, Canavesi M, et al. Human apolipoproteins A-I and A-II in cell cholesterol efflux. Studies with transgenic mice. Arterioscler Thromb Vasc Biol 1998; 18:1417-1423.
38. Remaley AT, Stonik JA, Demosky SJ, et al. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun 2001; 280:818-823.
39. Castellani LW, Navab M, van Lenten BJ, et al. Overexpression of apolipoprotein A-II in trangenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100:464-474.
40. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001; 108:793-797.
41. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 2001; 276:15641-15649.
42. Tall AR, Wang N, Mucksavage P. Is it time to modify the reverse cholesterol transport model? J Clin Invest 2001; 108:1273-1275. This very interesting review analyzes in-vivo studies questioning the quantitative importance of cholesterol efflux through ABCA1 in the formation of HDL.
43. Mackness MI, Durrington PN, Mackness B. How high density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000; 11:383-388.
44. Boisfer E, Stengel D, Pastier D, et al. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res 2002; 43:732-741. This study with human ape A-II transgenic mice showed that human ape A-II-rich HDLs efficiently transport antioxidant enzymes. Although VLDLs accumulate in the circulation of fed mice, they are not oxidized in the basal state. Indeed, apo A-II-rich HDLs protect VLDLs more efficiently from copper-induced oxidation than control HDLs.
45. Deakin S, Leviev I, Gomaraschi M, et al. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277:4301-4308. This study examined the mechanism of release of paraoxonase from producing cells. Ape A-I and A-II promote paraoxonase release only when they are reconstituted to HDL with phospholipid, whereas the free apolipoproteins do not substitute for HDL.
46. Paris exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002; 41:2089-2096. This study established that the presence of a cysteine in two apo A-I variants increases the antioxidant potential of apo A-I. This is a rare gain of function of a cysteine mutation.
47. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and A-II. J Biol Chem 1998; 273:6088-6095.
48. Escolà-Gil JC, Julve J, Marzal-Casacuberta A, et al. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. J Lipid Res 2000; 41:1328-1338.
49. Schultz JR, Gong EL, McCall MR, et al. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem 1992; 267:21630-21636.
50. Durbin DM, Jonas A. The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem 1997; 272:31333-31339.
51. 1-HDL may be the first product of apo A-I lipidation.
52. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994; 5:126-137.
53. Escolà-Gil JC, Marzal-Casacuberta A, Julve-Gil J, et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is overexpressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res 1998; 39:457-462.
54. Doolittle MH, LeBoeuf RC, Warden CH, et al. A polymorphism affecting apolipoprotein A-II translational efficiency determines high density lipoprotein size and composition. J Biol Chem 1990; 265:16380-16388.
55. Hedrick CC, Castellani LW, Warden CH, et al. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 1993; 268:20676-20682.
56. Warden CH, Hedrick CC, Qiao J-H, et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261:469-472.
57. Zhong S, Goldberg IJ, Bruce C, et al. Human apo A-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest 1994; 94:2457-2467.
58. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002; 16:185-194. This is the first study to show that apo A-II confers protection from development of hepatic steatosis following hepatitis C virus infection. Apo A-II binds part of virus core protein and induces its secretion. Thus, core does not inhibit microsomal triglyceride transfer protein activity and VLDL secretion, which is the cause of steatosis.
59. Julve J, Escolà-Gil JC, Marzal-Casacuberta A, et al. Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed a high-fat diet. Biochim Biophys Acta 2000; 1488:233-244.
60. Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes 2001; 50:643-651.
61. Warden CH, Daluiski A, Bu X, et al. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. Proc Natl Acad Sci U S A 1993; 90:10886-10890.
62. Weng W, Breslow JL. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci U S A 1996; 93:14788-14794.
63. Escolà-Gil JC, Blanco-Vaca F, Julve J. Overexpression of human apolipoprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity. Diabetologia 2002; 45:600-601. This report investigates several relevant parameters to establish a role of human apo A-II in susceptibility to insulin resistance, and to compare with the effects of murine apo A-II.
64. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47:1928-1934.